Skip to content
How It Works
Explore
Resources Ask a Question
Who It's For
Patients
Decode results, prep for appointments, weigh options.
Caregivers & advocates
Carry the research load for someone you love.
Providers & clinicians
Resources for patients in your practice.
Log In Ask a Question
PubMed This is a summary of 23 peer-reviewed journal articles Updated
Dermatology

Standard of Care Treatment for CLE

At a Glance

The standard of care for Cutaneous Lupus Erythematosus (CLE) involves a step-by-step approach starting with strict daily sun protection. Treatment progresses to topical creams like steroids or TCIs, systemic medications such as hydroxychloroquine, and targeted biologics for severe cases.

Managing Cutaneous Lupus Erythematosus (CLE) requires a tiered approach that starts with protecting the skin and progresses to systemic medications if the disease is widespread or resistant [1][2]. The goal is not just to clear current rashes, but to prevent permanent scarring and reduce the risk of the disease affecting internal organs [3].

The Foundation: Photoprotection

Because UV light is a direct trigger for the immune attack in CLE, strict photoprotection is the absolute baseline of care [4][5]. This is not “optional” advice; it is a clinical requirement.

  • Broad-spectrum Sunscreen: Use SPF 50+ containing physical blockers (like zinc oxide or titanium dioxide) to ensure high UVA protection. Apply daily, even on cloudy days or when indoors near windows, as UVA rays easily penetrate glass [6].
  • Proper Application: Sunscreen must be reapplied every 2 hours while outdoors, using adequate amounts (about a shot glass full for the body).
  • Behavioral Changes: Seek shade and wear UV-protective clothing. This baseline often makes other treatments more effective [4].
  • Vitamin D: Because strict sun avoidance can lead to deficiency, ask your doctor about starting a daily Vitamin D supplement.

The Treatment Decision Tree

Treatment is generally divided into Local (topical) and Systemic (pills or injections), following a step-by-step process [2][7].

Step 1: Localized Treatment

For many patients, especially those with limited lesions, treatment begins with:

  • Topical Corticosteroids: The first-line therapy for active flares [8][9]. However, long-term use can cause skin thinning (atrophy), so they must be used as directed [1].
  • Topical Calcineurin Inhibitors (TCIs): Medications like tacrolimus (ointment) or pimecrolimus (cream) [8]. Unlike steroids, these do not cause skin thinning, making them ideal for the face and long-term maintenance [8].

Step 2: First-Line Systemic Treatment

If skin disease is widespread or doesn’t respond to creams, doctors add antimalarials [1][10].

  • Hydroxychloroquine (HCQ): This is the “gold standard” systemic pill for skin lupus [10][11].
  • Beyond the Skin: HCQ is not just for symptoms. Early use has been shown to have a protective effect, potentially lowering the risk of CLE progressing into systemic lupus (SLE) [3].
  • Common Side Effects: HCQ can cause gastrointestinal upset, so it is best taken with food. Some patients also experience a harmless but noticeable blue-gray hyperpigmentation of the skin (which should not be confused with a lupus flare).
  • Eye Safety: While generally safe, long-term use requires periodic eye exams to monitor for rare retinal toxicity [12][13].

Step 3: Second-Line Systemic Treatment

If HCQ is not enough, other “off-label” medications may be used:

  • Immunosuppressants: Methotrexate, mycophenolate mofetil, or azathioprine are common choices [14][2].
  • Other Options: Dapsone (often used for specific subtypes) or systemic retinoids [1][15].

Refractory Disease and Newer Biologics

When standard treatments fail, the disease is considered refractory [16]. In these cases, newer, targeted therapies are used:

  • Anifrolumab: A newer biologic that blocks interferon, the primary driver of skin lupus [14][17]. It has shown significant efficacy in clearing severe skin lesions [18].
  • JAK Inhibitors: Medications like baricitinib or upadacitinib are an emerging “hot topic” in CLE research [19][20]. They target the signaling pathways that tell the immune system to attack [21].
  • Rituximab: A B-cell depletion therapy used in severe, recalcitrant cases [22][23].

Common Pitfalls in Treatment

Inexperienced providers may incorrectly use only steroids for long periods, which can lead to permanent skin damage and thinning. Modern consensus emphasizes “steroid-sparing” agents like TCIs or antimalarials as soon as possible [1]. Additionally, failing to address lifestyle factors like smoking cessation—which can make hydroxychloroquine significantly less effective—is a common oversight [4].

Common questions in this guide

Why is strict sun protection required for cutaneous lupus?
UV light directly triggers the immune system to attack the skin in cutaneous lupus. Strict photoprotection, including SPF 50+ broad-spectrum sunscreen and UV-protective clothing, is a clinical requirement to prevent flares and make other treatments more effective.
What is the first-line systemic treatment for skin lupus?
Hydroxychloroquine is considered the gold standard pill for skin lupus that doesn't respond to topical creams. Not only does it help clear skin symptoms, but early use may also help protect against the disease progressing to systemic lupus.
Do I need eye exams if I take hydroxychloroquine for CLE?
Yes. While hydroxychloroquine is generally safe, long-term use requires periodic eye exams to monitor for a rare side effect called retinal toxicity. Always report any vision changes to your doctor.
What are topical calcineurin inhibitors (TCIs) used for?
TCIs like tacrolimus and pimecrolimus are creams used to treat active skin lupus flares. Unlike topical steroids, they do not cause skin thinning, making them a safer option for use on the face and for long-term maintenance.
What happens if standard treatments for CLE don't work?
If the disease does not respond to standard medications, doctors may prescribe newer biologic therapies like anifrolumab or JAK inhibitors. These targeted therapies block specific pathways that drive the immune system attack on the skin.

Questions to Ask Your Doctor

Curated prompts to bring to your next appointment.

  1. 1.Am I currently on the maximum safe weight-based dose of hydroxychloroquine?
  2. 2.How long should we wait to see if my current treatment is working before moving to the next 'step'?
  3. 3.Based on my subtype, should we consider adding a topical calcineurin inhibitor instead of more steroids?
  4. 4.If my skin does not respond to first-line agents, what is the protocol for accessing newer biologics like anifrolumab?
  5. 5.Should I consider a Vitamin D supplement due to my strict sun protection regimen?

Questions For You

Tap a prompt to share your answer — we'll use it plus this page's context to start a tailored conversation.

References

References (23)
  1. 1

    Update on cutaneous lupus erythematosus pathogenesis, diagnosis and management.

    Chasset F, Teboul A

    Journal of the European Academy of Dermatology and Venereology : JEADV 2026; (40(5)):782-800 doi:10.1111/jdv.70186.

    PMID: 41328032
  2. 2

    An update on the management of refractory cutaneous lupus erythematosus.

    Verdelli A, Corrà A, Mariotti EB, et al.

    Frontiers in medicine 2022; (9()):941003 doi:10.3389/fmed.2022.941003.

    PMID: 36213629
  3. 3

    Early initiation of hydroxychloroquine in cutaneous lupus erythematosus to prevent progression to systemic lupus erythematosus: A long-term follow-up study.

    Bar D, Baum S, Segal Z, et al.

    Journal of the American Academy of Dermatology 2025; (93(1)):55-63 doi:10.1016/j.jaad.2025.02.066.

    PMID: 40015570
  4. 4

    Cutaneous lupus erythematosus: clinico-pathologic correlation.

    Filotico R, Mastrandrea V

    Giornale italiano di dermatologia e venereologia : organo ufficiale, Societa italiana di dermatologia e sifilografia 2018; (153(2)):216-229 doi:10.23736/S0392-0488.18.05929-1.

    PMID: 29368845
  5. 5

    Subacute cutaneous lupus erythematosus-like drug eruption after durvalumab treatment for squamous cell carcinoma.

    Giger D, Del Mundo DY, Avashia-Khemka N

    Dermatology online journal 2025; (31(5)) doi:10.25251/10agjt29.

    PMID: 41725481
  6. 6

    Case Report: Subacute cutaneous lupus erythematosus induced by the anti-PD-1 antibody camrelizumab combined with chemotherapy.

    Bao H, Zhang J, Luo X, et al.

    Frontiers in immunology 2025; (16()):1539373 doi:10.3389/fimmu.2025.1539373.

    PMID: 40226630
  7. 7

    Cutaneous Lupus Erythematosus: An Update on Pathogenesis, Diagnosis and Treatment.

    Hejazi EZ, Werth VP

    American journal of clinical dermatology 2016; (17(2)):135-46 doi:10.1007/s40257-016-0173-9.

    PMID: 26872954
  8. 8

    Efficacy and safety of calcineurin inhibitors in cutaneous lupus: a systematic review and brief meta-analysis of recommended concentration, type, and outcomes.

    Alshathri AH, Abdellatif RA, Alshathri AH, et al.

    Annals of medicine and surgery (2012) 2025; (87(5)):2880-2888 doi:10.1097/MS9.0000000000003047.

    PMID: 40337382
  9. 9

    Manifestation of subacute cutaneous lupus erythematosus during treatment with anti-PD-1 antibody cemiplimab - a case report.

    Fietz S, Fröhlich A, Mauch C, et al.

    Frontiers in immunology 2023; (14()):1324231 doi:10.3389/fimmu.2023.1324231.

    PMID: 38143738
  10. 10

    Efficacy and comparison of antimalarials in cutaneous lupus erythematosus subtypes: a systematic review and meta-analysis.

    Chasset F, Bouaziz JD, Costedoat-Chalumeau N, et al.

    The British journal of dermatology 2017; (177(1)):188-196 doi:10.1111/bjd.15312.

    PMID: 28112801
  11. 11

    Widespread subacute cutaneous lupus erythematosus in a patient receiving checkpoint inhibitor immunotherapy with ipilimumab and nivolumab.

    Kosche C, Owen JL, Choi JN

    Dermatology online journal 2019; (25(10)).

    PMID: 31735010
  12. 12

    Hydroxychloroquine in systemic lupus erythematosus: overview of current knowledge.

    Dima A, Jurcut C, Chasset F, et al.

    Therapeutic advances in musculoskeletal disease 2022; (14()):1759720X211073001 doi:10.1177/1759720X211073001.

    PMID: 35186126
  13. 13

    Comment on the 2019 update of the EULAR recommendations for the management of systemic lupus erythematosus by Fanouriakis et al.

    Costedoat-Chalumeau N, Isenberg D, Petri M

    Annals of the rheumatic diseases 2020; (79(8)):e90 doi:10.1136/annrheumdis-2019-215573.

    PMID: 31048291
  14. 14

    Case series of anifrolumab for treatment of cutaneous lupus erythematosus and lupus-related mucocutaneous manifestations in patients with SLE.

    Bao A, Petri MA, Fava A, Kang J

    Lupus science & medicine 2023; (10(2)) doi:10.1136/lupus-2023-001007.

    PMID: 38114267
  15. 15

    A review of the evidence and cost of therapies for cutaneous lupus erythematosus.

    Rosen JD, Paul S, Maderal A

    Lupus 2019; (28(7)):799-805 doi:10.1177/0961203319846397.

    PMID: 31042129
  16. 16

    Successful use of anifrolumab in refractory cutaneous lupus erythematosus with systemic lupus erythematosus: A case report.

    Ramadhan A, Troug A, Yacyshyn E, Gniadecki R

    SAGE open medical case reports 2025; (13()):2050313X251350376 doi:10.1177/2050313X251350376.

    PMID: 40589849
  17. 17

    Anifrolumab for the treatment of cutaneous lupus erythematosus: a 10-case series.

    Hernández-Salas ME, Horcajada-Reales C, Palomar-Prieto C, et al.

    Clinical and experimental dermatology 2025; (50(10)):2040-2043 doi:10.1093/ced/llaf272.

    PMID: 40577812
  18. 18

    Alopecia secondary to severe discoid lupus responding to anifrolumab.

    Han S, Ferrer J, Bittar M, Jones A

    International journal of women's dermatology 2023; (9(3)):e098 doi:10.1097/JW9.0000000000000098.

    PMID: 37497192
  19. 19

    Oral tofacitinib citrate for recalcitrant cutaneous lupus.

    Bonnardeaux E, Dutz JP

    JAAD case reports 2022; (20()):61-64 doi:10.1016/j.jdcr.2021.09.030.

    PMID: 35118185
  20. 20

    Advancements in the Treatment of Cutaneous Lupus Erythematosus and Dermatomyositis: A Review of the Literature.

    Elhage KG, Zhao R, Nakamura M

    Clinical, cosmetic and investigational dermatology 2022; (15()):1815-1831 doi:10.2147/CCID.S382628.

    PMID: 36105749
  21. 21

    Cutaneous lupus erythematosus: new insights into pathogenesis and therapeutic strategies.

    Wenzel J

    Nature reviews. Rheumatology 2019; (15(9)):519-532 doi:10.1038/s41584-019-0272-0.

    PMID: 31399711
  22. 22

    Refractory discoid lupus erythematosus responds to rituximab.

    Mumford BP, Assarian Z, Oon S, Chong AH

    The Australasian journal of dermatology 2021; (62(2)):e341-e343 doi:10.1111/ajd.13514.

    PMID: 33216961
  23. 23

    Intravenous Immunoglobulin in the Management of Lupus Erythematosus Panniculitis.

    AlQadri NG, AlNooh B, AlTewerki MM, et al.

    Cureus 2020; (12(1)):e6790 doi:10.7759/cureus.6790.

    PMID: 32025447

This page provides information on standard treatments for cutaneous lupus erythematosus (CLE) for educational purposes only. Always consult your dermatologist or rheumatologist before starting or changing medications.

Get notified when new evidence is published on Cutaneous lupus erythematosus.

We monitor PubMed for new peer-reviewed studies on this topic and email a short summary when something meaningful changes.